Eurican Lmulti Suspension for Injection

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: VMD (Veterinary Medicines Directorate)

Veiklioji medžiaga:

Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae

Prieinama:

Boehringer Ingelheim Animal Health UK Ltd

ATC kodas:

QI07AB01

INN (Tarptautinis Pavadinimas):

Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae

Vaisto forma:

Suspension for injection

Recepto tipas:

POM-V - Prescription Only Medicine – Veterinarian

Farmakoterapinė grupė:

Dogs

Gydymo sritis:

Inactivated Bacterial Vaccine

Autorizacija statusas:

Authorized

Leidimo data:

2015-12-10

Prekės savybės

Revised: September 2020
AN: 01797/2019
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Lmulti Suspension for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (1ml) of suspension contains:
ACTIVE SUBSTANCES:
Inactivated_ Leptospira interrogans _serogroup_ _ and serovar Canicola
strain 16070
......................................................................Activity
acc. to Ph. Eur.447*
Inactivated_ Leptospira interrogans _serogroup and serovar _
_Icterohaemorrhagiae
strain16069
.......................................................................Activity
acc. to Ph. Eur.447*
Inactivated _Leptospira interrogans _serogroup and serovar_
_Grippotyphosa
strain Grippo Mal 1540
..........................................................Activity
acc. to Ph. Eur.447*
*

80% protection in hamsters
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Opalescent and homogenous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to:
-
prevent mortality, clinical signs, infection, bacterial excretion,
renal carriage and
renal
lesions
caused
by
_Leptospira_
interrogans
serogroup
Icterohaemorrhagiae
serovar Icterohaemorrhagiae
-
prevent mortality* and clinical signs, reduce infection, bacterial
excretion, renal
carriage and renal lesions caused by _ Leptospira_ interrogans
serogroup Canicola
serovar Canicola.
-
prevent mortality*, and reduce clinical signs, infection, bacterial
excretion renal
carriage and renal lesions caused by _Leptospira_ kirschneri serogroup
Grippotyphosa
serovar Grippotyphosa.
Revised: September 2020
AN: 01797/2019
Page 2 of 5
-
prevent
mortality,
clinical
signs,
renal
infection,
bacterial
excretion,
renal
carriage
and
renal
lesions
caused
by
_Leptospira_
_interrogans_
serogroup
Icterohaemorrhagiae serovar Copenhageni.**
Onset of immunity: 2 weeks after the second injection of the primary
v